KUALA LUMPUR 2 July - Genetic screening and genome analysis provider, Malaysian Genomics Resource Centre (MGRC) Berhad is adding companion diagnostics and cancer immunotherapy based on Chimeric Antigen Receptor (CAR) T-cells to its portfolio of products and services in Southeast Asia.
The portfolio expansion offers MGRC in securing exclusive licensing rights for this country, Singapore, Thailand, and five other Southeast Asian nations related to CAR T-Cell therapy for solid cancers of organs such as the liver, pancreas and stomach.
MGRC Chief Operating Officer, Sasha Nordin said, the firm will be among the first companies to offer such cutting-edge services in Southeast Asia.
“Companion diagnostics and cancer immunotherapy based on CAR T-cells will enhance our portfolio of personalized healthcare products and services for doctors and medical centres.
“In the longer run, we are looking to explore CAR T-cell therapies for liquid cancers such as lymphoma and leukemia, and we might also explore the possibility of developing our own CAR T-cell production lab,” said Sasha.
Notably, CAR T-cell therapy uses patients’ own blood to produce T-cells with CARs on their surface. Laboratory testing is important both before therapy to evaluate patients’ suitability and after therapy to monitor the treatment’s effectiveness.
“We have been in genomics services and genetics testing for more than 15 years, and we have the necessary strengths to support the healthcare community’s drive towards personalized care. This is a great opportunity to contribute our genomics and genetics experience towards improvements in fighting cancer,” he added.
For the record, iCARTab has developed a CAR T-cell therapy for solid cancers and currently operates two state of the art laboratories in Ningbo and Shandung, China for cell manufacturing at a combined 100,000 sqf of lab space.
Cancers of the lung and liver are two of the most common solid cancers in Southeast Asia. Those of the liver, pancreas, oesophagus, brain and central nervous system, stomach, and mesothelioma in the lungs are among the 10 cancers with the lowest 5-year survival rates. - DagangNews.com
Layari kami terus di DagangNews.com dan juga
Orang ramai yang ingin memberi pandangan atau suara hati, boleh menghantar tulisan ke suratpembaca@dagangnews.com dengan menyatakan:
1. Nama Pena (Jika tidak mahu guna nama sebenar).
2. Nama Sebenar seperti dalam Kad Pengenalan (Untuk rekod kami).
3. No. Telefon (untuk kami hubungi semula).
4. Menulis mengikut 5 Prinsip Rukun Negara.
5. Tidak melebihi 1,000 patah perkataan.
6. Editor berhak untuk menyunting atau menolak artikel secara profesional.
